Overview

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Status:
Terminated

Trial end date:
2021-04-08

Target enrollment:

Participant gender:

Summary

This study will explore the safety and antiviral activity of ABI-H0731 when added to a nucleos(t)ide reverse transcriptase inhibitor (NrtI) in participants who are partially virologically suppressed.

Phase:

Phase 2

Details

Lead Sponsor:

Assembly Biosciences

Treatments:

Reverse Transcriptase Inhibitors